Company Overview - Samsung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, Samsung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 5.728 billion yuan, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 18, Samsung Medical's stock price decreased by 2.02%, trading at 22.75 yuan per share, with a total market capitalization of 31.969 billion yuan. The stock has declined by 23.85% year-to-date [1]. - The stock's trading volume showed a net inflow of 4.8744 million yuan from main funds, with significant buying and selling activities recorded [1]. Shareholder Information - As of June 30, the number of shareholders increased to 29,000, up by 76.91%, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The company's main business revenue composition includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses, with no revenue from financing leasing and consulting services [1]. - Samsung Medical is categorized under the electric equipment industry, specifically in the distribution equipment sector, and is associated with concepts such as private hospitals, mid-cap stocks, electric IoT, industrial internet, and energy storage [1].

9月18日，新钢股份盘中下跌2.08%，截至13:55，报4.23元/股，成交1.99亿元，换手率1.49%，总市值 134.62亿元。 分红方面，新钢股份A股上市后累计派现55.84亿元。近三年，累计派现8.16亿元。 机构持仓方面，截止2025年6月30日，新钢股份十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股3397.21万股，相比上期减少680.59万股。中欧红利优享灵活配置混合A（004814）位居第 五大流通股东，持股3119.50万股，为新进股东。汇丰晋信新动力混合A（000965）位居第八大流通股 东，持股2543.47万股，相比上期减少2372.76万股。睿远均衡价值三年持有混合A（008969）、汇丰晋 信大盘股票A（540006）、东方红启恒三年持有混合A（910004）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，新余钢铁股份有限公司位于江西省新余市冶金路1号，成立日期2003年10月10日，上市日期 1996年12月25日，公司主营业务涉及钢铁冶炼、钢材轧制及钢材延伸加工及其产品的制造、销售。主营 业务收入构成为：钢材及钢绞线收入89.63%，其他收入10.3 ...

资料显示，重庆涪陵电力实业股份有限公司位于重庆市涪陵区望州路20号，成立日期1999年12月29日， 上市日期2004年3月3日，公司主营业务涉及电力供应业务、配电网节能业务。主营业务收入构成为：电 力销售及工程安装63.74%，节能服务36.18%，其他(补充)0.09%。 涪陵电力所属申万行业为：公用事业-电力-电能综合服务。所属概念板块包括：央企改革、西部开发、 中盘、节能环保、电力物联网等。 截至6月30日，涪陵电力股东户数4.65万，较上期增加37.40%；人均流通股33014股，较上期减少 27.22%。2025年1月-6月，涪陵电力实现营业收入14.16亿元，同比减少3.86%；归母净利润1.67亿元，同 比减少14.95%。 分红方面，涪陵电力A股上市后累计派现11.56亿元。近三年，累计派现5.39亿元。 机构持仓方面，截止2025年6月30日，涪陵电力十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股1166.81万股，相比上期减少352.88万股。南方中证1000ETF（512100）位居第十大流通股 东，持股852.87万股，为新进股东。 9月18日，涪陵电力盘中下跌2.0 ...

9月18日，西南证券盘中下跌2.03%，截至13:47，报4.83元/股，成交2.06亿元，换手率0.63%，总市值 320.96亿元。 资金流向方面，主力资金净流出4272.99万元，特大单买入348.24万元，占比1.69%，卖出3197.04万元， 占比15.53%；大单买入3451.76万元，占比16.77%，卖出4875.95万元，占比23.69%。 西南证券今年以来股价涨4.89%，近5个交易日跌1.83%，近20日跌1.02%，近60日涨11.42%。 资料显示，西南证券股份有限公司位于重庆市江北区金沙门路32号西南证券总部大楼，成立日期1990年 6月7日，上市日期2001年1月9日，公司主营业务涉及证券类金融业务。主营业务收入构成为：经纪业务 54.45%，自营业务30.51%，其他业务8.37%，投资银行业务6.03%，资产管理业务0.64%。 西南证券所属申万行业为：非银金融-证券Ⅱ-证券Ⅲ。所属概念板块包括：期货概念、DeepSeek概念、 国资改革、低价、中盘等。 截至6月30日，西南证券股东户数12.15万，较上期减少3.94%；人均流通股51991股，较上期增加 4.11%。20 ...

江阴银行今年以来股价涨11.33%，近5个交易日跌6.29%，近20日跌8.15%，近60日跌6.85%。 9月18日，江阴银行盘中下跌2.12%，截至13:46，报4.62元/股，成交1.15亿元，换手率1.00%，总市值 113.72亿元。 截至8月20日，江阴银行股东户数4.52万，较上期增加0.22%；人均流通股54326股，较上期减少0.22%。 2025年1月-6月，江阴银行实现营业收入0.00元；归母净利润8.46亿元，同比增长16.63%。 资金流向方面，主力资金净流出1770.64万元，特大单买入0.00元，占比0.00%，卖出641.57万元，占比 5.60%；大单买入1477.66万元，占比12.90%，卖出2606.72万元，占比22.75%。 资料显示，江苏江阴农村商业银行股份有限公司位于中国江苏省江阴市澄江中路1号银信大厦11楼，成 立日期2001年12月3日，上市日期2016年9月2日，公司主营业务涉及吸收公众存款;发放短期,中期和长 期贷款;办理国内结算;办理票据承兑与贴现等金融业务。主营业务收入构成为：公司业务43.78%，个人 业务33.09%，资金任务22.34%，其他0 ...

Core Viewpoint - Dongxing Securities experienced a decline in stock price, with a current trading price of 11.63 yuan per share and a market capitalization of 37.593 billion yuan, reflecting a net outflow of funds [1] Company Overview - Dongxing Securities was established on May 28, 2008, and listed on February 26, 2015. The company is located in Beijing and engages in various financial services including securities brokerage, investment banking, asset management, proprietary trading, alternative investments, credit trading, futures, and direct investments [1] - The main revenue sources for Dongxing Securities are wealth management (38.98%), investment trading (37.14%), investment banking (11.16%), other businesses (6.78%), and asset management (5.94%) [1] Financial Performance - As of June 30, 2025, Dongxing Securities reported a net profit of 821 million yuan, representing a year-on-year growth of 42.12%. However, the company recorded zero operating revenue for the first half of 2025 [2] - The company has distributed a total of 4.81 billion yuan in dividends since its A-share listing, with 957 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Dongxing Securities had 113,200 shareholders, a decrease of 3.79% from the previous period. The average number of circulating shares per shareholder increased by 3.94% to 28,558 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable changes in their holdings [3]

9月18日，奕瑞科技盘中下跌2.02%，截至13:46，报111.70元/股，成交2.48亿元，换手率1.09%，总市值 223.64亿元。 奕瑞科技所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：口腔医疗、专精特新、 融资融券、中盘、增持回购等。 截至6月30日，奕瑞科技股东户数6990.00，较上期增加21.67%；人均流通股28643股，较上期增加 15.02%。2025年1月-6月，奕瑞科技实现营业收入10.67亿元，同比增长3.94%；归母净利润3.35亿元，同 比增长8.82%。 分红方面，奕瑞科技A股上市后累计派现7.89亿元。近三年，累计派现5.57亿元。 机构持仓方面，截止2025年6月30日，奕瑞科技十大流通股东中，华宝中证医疗ETF（512170）位居第 九大流通股东，持股392.60万股，为新进股东。景顺长城新能源产业股票A类（011328）退出十大流通 股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出679.79万元，特大单买入1264.27万元，占比5.10%，卖出3179.83万元， 占比12.83%；大单买入5865.77万元，占比23.67%，卖出 ...

资料显示，中泰证券股份有限公司位于山东省济南市市中区经七路86号，成立日期2001年5月15日，上 市日期2020年6月3日，公司主营业务涉及证券经纪;证券投资咨询;与证券交易、证券投资活动有关的财 务顾问;证券承销与保荐;证券自营;融资融券;证券投资基金代销;代销金融产品;股票期权做市;证券投资基 金托管等。同时,本公司通过控股子公司中泰资管、鲁证期货、中泰资本、中泰创投和中泰国际分别从 事资产管理业务、期货业务、私募投资基金业务、另类投资业务和含香港市场在内的境外业务等。主营 业务收入构成为：财富管理业务37.46%，资产管理业务22.53%，投资业务12.50%，信用业务11.08%， 期货业务7.91%，投资银行业务4.97%，其他业务3.78%。 中泰证券所属申万行业为：非银金融-证券Ⅱ-证券Ⅲ。所属概念板块包括：参股基金、期货概念、中 盘、融资融券、山东国资等。 9月18日，中泰证券盘中下跌2.27%，截至13:45，报6.88元/股，成交1.36亿元，换手率0.50%，总市值 476.21亿元。 机构持仓方面，截止2025年6月30日，中泰证券十大流通股东中，香港中央结算有限公司位居第七大流 通 ...

Core Viewpoint - Xinhua Medical's stock price has shown fluctuations, with a recent decline of 2.10% and a total market capitalization of 10.192 billion yuan, indicating potential investor concerns and market dynamics [1]. Financial Performance - For the first half of 2025, Xinhua Medical reported operating revenue of 4.79 billion yuan, a year-on-year decrease of 7.64%, and a net profit attributable to shareholders of 386 million yuan, down 20.35% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 812 million yuan, with 455 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Xinhua Medical reached 39,300, an increase of 0.82% from the previous period, while the average circulating shares per person decreased by 0.81% to 15,386 shares [2]. - The top three circulating shareholders include Huabao Zhongzheng Medical ETF, holding 16.0931 million shares (an increase of 196,600 shares), and Hong Kong Central Clearing Limited, holding 7.9202 million shares (an increase of 413,000 shares) [3]. Business Overview - Xinhua Medical, established on April 18, 1993, and listed on September 27, 2002, operates primarily in the medical device and pharmaceutical equipment sectors, with a revenue composition of 35.16% from medical device manufacturing, 31.23% from medical trade, 24.43% from pharmaceutical equipment, 7.05% from medical services, and 2.12% from other sources [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and equipment, and is involved in various concept sectors including mid-cap, medical waste treatment, in vitro diagnostics, smart healthcare, and private hospitals [1].

Core Viewpoint - The stock price of Jinhuijiu has experienced fluctuations, with a year-to-date increase of 9.00% but a recent decline of 8.44% over the past five trading days [2]. Group 1: Stock Performance - As of September 18, Jinhuijiu's stock price was 20.83 CNY per share, with a market capitalization of 10.566 billion CNY [1]. - The stock has seen a 3.48% increase over the past 20 days and a 15.21% increase over the past 60 days [2]. - The trading volume on September 18 was 1.19 billion CNY, with a turnover rate of 1.11% [1]. Group 2: Financial Performance - For the first half of 2025, Jinhuijiu reported a revenue of 1.759 billion CNY, representing a year-on-year growth of 0.31%, and a net profit attributable to shareholders of 298 million CNY, up 1.12% year-on-year [2]. - The company has distributed a total of 1.168 billion CNY in dividends since its A-share listing, with 598 million CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Jinhuijiu was 44,500, a decrease of 7.68% from the previous period [2]. - The average number of circulating shares per shareholder increased by 8.32% to 11,408 shares [2]. - The sixth largest circulating shareholder is the China Securities White Wine Index A, holding 20.9613 million shares, an increase of 6.4165 million shares from the previous period [3].